Technical Analysis for LGVN - Longeveron Inc.

Grade Last Price % Change Price Change
F 2.74 1.48% 0.04
LGVN closed up 1.48 percent on Wednesday, March 22, 2023, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Low Weakness 1.48%
Wide Bands Range Expansion 1.48%
Lower Bollinger Band Touch Weakness 1.48%
Oversold Stochastic Weakness 1.48%
New 52 Week Closing Low Bearish 1.48%
New 52 Week Low Weakness 1.48%
Wide Bands Range Expansion 1.48%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 11 hours ago
Up 1 ATR about 11 hours ago
Rose Above Previous Day's High about 13 hours ago
Up 3% about 13 hours ago
Up 2% about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Longeveron Inc. Description

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Cell Therapy Cell Biology Acute Respiratory Distress Syndrome Mesenchymal Stem Cell Alzheimer’s Disease

Is LGVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 16.77
52 Week Low 2.5
Average Volume 37,882
200-Day Moving Average 4.46
50-Day Moving Average 3.58
20-Day Moving Average 3.22
10-Day Moving Average 2.90
Average True Range 0.18
RSI 23.66
ADX 32.92
+DI 12.41
-DI 33.89
Chandelier Exit (Long, 3 ATRs) 3.15
Chandelier Exit (Short, 3 ATRs) 3.05
Upper Bollinger Bands 3.93
Lower Bollinger Band 2.51
Percent B (%b) 0.16
BandWidth 44.12
MACD Line -0.25
MACD Signal Line -0.19
MACD Histogram -0.055
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.09
Resistance 3 (R3) 3.10 2.99 3.03
Resistance 2 (R2) 2.99 2.90 2.99 3.01
Resistance 1 (R1) 2.87 2.84 2.93 2.86 2.99
Pivot Point 2.76 2.76 2.79 2.75 2.76
Support 1 (S1) 2.63 2.67 2.69 2.62 2.49
Support 2 (S2) 2.52 2.61 2.52 2.47
Support 3 (S3) 2.40 2.52 2.45
Support 4 (S4) 2.39